Nutriband Inc. (NTRB)
NASDAQ: NTRB · Real-Time Price · USD
5.85
-0.80 (-12.03%)
At close: Oct 12, 2026, 4:00 PM EDT
5.85
0.00 (0.00%)
After-hours: Oct 12, 2026, 4:10 PM EDT
Nutriband Revenue
Nutriband had revenue of $437.51K in the quarter ending July 31, 2026, a decrease of -29.71%. This brings the company's revenue in the last twelve months to $1.62M, down -37.25% year-over-year. In the fiscal year ending January 31, 2026, Nutriband had annual revenue of $2.04M, down -4.81%. That makes Nutriband the 42,766th largest company in the world by revenue and 5,870th in the United States.
Revenue (ttm)
$1.62M
Revenue Growth
-37.25%
P/S Ratio
49.97
Revenue / Employee
$124,437
Employees
13
Market Cap
71.11M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jan 31, 2026 | 2.04M | -102.89K | -4.81% |
| Jan 31, 2025 | 2.14M | 54.22K | 2.60% |
| Jan 31, 2024 | 2.09M | 5.71K | 0.27% |
| Jan 31, 2023 | 2.08M | 657.46K | 46.23% |
| Jan 31, 2022 | 1.42M | 478.45K | 50.70% |
| Jan 31, 2021 | 943.70K | 573.06K | 154.61% |
| Jan 31, 2020 | 370.65K | 125.36K | 51.11% |
| Jan 31, 2019 | 245.29K | - | - |
| Jan 31, 2018 | - | - | - |
| Jan 31, 2017 | - | - | - |
| Jan 31, 2016 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Heron Therapeutics | 151.18M |
| Pelthos Therapeutics | 43.30M |
| NeurAxis | 5.32M |
| MediciNova | 920.48K |
| Cardiff Oncology | 508.00K |
NTRB News
- 4 days ago - Nutriband files non-provisional utility Aversa patent application with USPTO - TheFly
- 4 days ago - Nutriband Files New Patent Application to Strengthen Intellectual Property Protection of Its Transdermal Abuse Deterrent Technology - GlobeNewsWire
- 11 days ago - Nutriband Marks Five Years on Nasdaq – CEO Letter to Shareholders - GlobeNewsWire
- 13 days ago - Nutriband CEO Gareth Sheridan Featured in New Nick Shirley Documentary Confronting America's Opioid Crisis - GlobeNewsWire
- 17 days ago - Nutriband appoints O’Neill to Advisory Board - TheFly
- 20 days ago - Nutriband Confirms Warrants Will Expire September 30 Without Extension or Repricing - GlobeNewsWire
- 4 weeks ago - Nutriband CEO, Gareth Sheridan to Attend the Nasdaq Life Sciences Advisory Board (LaB) Biotech Summit - GlobeNewsWire
- 4 weeks ago - Nutriband receives notice of publication from USPTO - TheFly